RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 Concomitant DMARD Therapies Increase Adalimumab Serum Concentrations in Patients with Rheumatic Diseases
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 17
SP 23
OP 23
DO 10.1177/155989771417015
UL http://mdc.sagepub.com/content/14/17/23.abstract
AB Patients with rheumatoid arthritis (RA) who are treated with adalimumab plus methotrexate (MTX) have higher serum trough levels of adalimumab and a better clinical response to therapy than patients treated with adalimumab alone [Pouw MF et al. Ann Rheum Dis 2013]. This article discusses the effect on adalimumab serum concentrations in patients with RA or psoriatic arthritis taking concomitant MTX and concomitant disease-modifying antirheumatic drugs (DMARDs) other than MTX.